Format

Send to

Choose Destination
Hum Vaccin Immunother. 2017 Jul 3;13(7):1640-1652. doi: 10.1080/21645515.2017.1313375. Epub 2017 May 22.

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.

Author information

1
a GSK , Wavre , Belgium.
2
b Business & Decision Life Sciences , Brussels , Belgium (on behalf of GSK).
3
c GSK , Philadelphia , PA , USA.

Abstract

The contribution of influenza B to the seasonal influenza burden varies from year-to-year. Although 2 antigenically distinct influenza B virus lineages have co-circulated since 2001, trivalent influenza vaccines (TIVs) contain antigens from only one influenza B virus. B-mismatch or co-circulation of both B lineages results in increased morbidity and mortality attributable to the B lineage absent from the vaccine. Quadrivalent vaccines (QIVs) contain both influenza B lineages. We reviewed currently licensed QIVs and their value by focusing on the preventable disease burden. Modeling studies support that QIVs are expected to prevent more influenza cases, hospitalisations and deaths than TIVs, although estimates of the case numbers prevented vary according to local specificities. The value of QIVs is demonstrated by their capacity to broaden the immune response and reduce the likelihood of a B-mismatched season. Some health authorities have preferentially recommended QIVs over TIVs in their influenza prevention programmes.

KEYWORDS:

influenza; influenza B; mismatch; quadrivalent influenza vaccine

PMID:
28532276
PMCID:
PMC5512791
DOI:
10.1080/21645515.2017.1313375
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center